

CITATION REPORT

List of articles citing

Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events

DOI: 10.1371/journal.pone.0080242
PLoS ONE, 2013, 8, e80242.

Source: <https://exaly.com/paper-pdf/87000771/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
33	Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint. <i>Aids</i> , 2014 , 28, 2477-80	3.5	10
32	Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 368-74	1.6	5
31	Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?. <i>PLoS ONE</i> , 2016 , 11, e0149562	3.7	
30	Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection. <i>PLoS ONE</i> , 2016 , 11, e0168709	3.7	5
29	What do we know about tailoring treatment with tenofovir?. <i>Pharmacogenomics</i> , 2016 , 17, 531-4	2.6	4
28	Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens. <i>Aids</i> , 2016 , 30, 1221-8	3.5	13
27	Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. <i>Aids</i> , 2016 , 30, 609-18	3.5	27
26	When food can make the difference: The case of elvitegravir-based co-formulation. <i>International Journal of Pharmaceutics</i> , 2016 , 512, 301-304	6.5	7
25	Determinants of bone diseases in tenofovir-treated HIV patients. <i>Aids</i> , 2016 , 30, 1686-7	3.5	1
24	Abacavir-induced liver toxicity. <i>Brazilian Journal of Infectious Diseases</i> , 2016 , 20, 502-4	2.8	8
23	Significant intolerability of efavirenz in HIV occupational postexposure prophylaxis. <i>Journal of Hospital Infection</i> , 2016 , 92, 372-7	6.9	1
22	Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017 , 42, 559-572	2.7	3
21	Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1137-1146	5.1	10
20	Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV. <i>Pharmacogenomics Journal</i> , 2018 , 18, 245-250	3.5	5
19	Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 77, 86-92	3.1	19
18	Categorization and association analysis of risk factors for adverse drug events. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 389-404	2.8	16
17	Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	115

16	Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1335-1342	11.6	39
15	Long term renal function in Asian HIV-1 infected adults receiving tenofovir disoproxil fumarate without protease inhibitors. <i>Journal of Infection</i> , 2019 , 79, 454-461	18.9	0
14	A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients. <i>Pharmacotherapy</i> , 2019 , 39, 1179-1189	5.8	4
13	Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. <i>Journal of Infectious Diseases</i> , 2019 , 220, 635-642	7	26
12	Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 64-74	3.2	6
11	Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 818-825	3.4	2
10	Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 463-474	5.5	9
9	Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP. <i>Aids</i> , 2021 , 35, 522-524	3.5	
8	Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021 , 86, 473-481	3.1	2
7	Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	0
6	Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar. <i>PLoS ONE</i> , 2015 , 10, e0135188	3.7	13
5	Bio-analytical Assay Methods used in Therapeutic Drug Monitoring of Antiretroviral Drugs-A Review. <i>Current Drug Therapy</i> , 2019 , 14, 16-57	0.7	2
4	Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea. <i>Korean Journal of Internal Medicine</i> , 2019 , 34, 409-417	2.5	5
3	Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens. <i>Aids</i> , 2021 , 35, 2551-2553	3.5	0
2	Antiretrovirals for People with HIV on Dialysis.. <i>AIDS Patient Care and STDs</i> , 2022 , 36, 86-96	5.8	1
1	Tenofovir-induced osteopenia and hyperparathyroidism: A case report and literature review. 13,		0